Abstract:
Objective
To observe the clinical effect and safety of meglumine adenosine cyclophosphate in the treatment of infants with asthmatic diseases.
Methods
A total of 100 cases of infantile asthmatic diseases treated in Tongling Maternal and Child Healthcare Hospital from Aug. 2014 to June 2016 were randomly divided into two groups: observation group and control group, 50 cases in each. Both groups were given conventional treatment; in addition, the observation group was given meglumine adenosine cyclophosphate injection for intravenous dripping and budisonide for inhalation, while the control group received methylprednisolone injection for intravenous dripping and budisonide for inhalation, the treatment lasting for 5 days. Observe the clinical effect, the time for wheezing, cough and pulmonary symptoms to be relieved, the length of hospital stay and adverse reactions in the children of the two groups.
Results
The total effective rate was 98.0%(49/50) in the observation group, and 96.0%(48/50) in the control group, there being no statistical difference between the two groups(P>0.05). There was no statistical difference in the relief time of such clinical symptoms as cough, wheezing, lung wheezing rales or the length of hospital stay between the two groups(P>0.05). There was no adverse reaction in both groups. There were 4 cases of infection in the control group because of the use of glucocorticoid in the whole body.
Conclusion
The effect of meglumine adenosine cyclophosphate in the treatment of infants with asthmatic diseases is similar to that of the use of glucocorticoid in the whole body; it's safe and worthy of clinical application.

Key words: Asthmatic disease, Meglumine adenosine cyclophosphate, Infant